& Stock Market Media
Helloooo, 360!
Welcome us back, we took a little summer vacation!
But our TOP trading room didn’t take a vacation – join us in Market Masters starting NOW. And here are some of our top movers today. Be the best prepared trader on the Street!
FOCUS LIST🔎
MYGN – Up over 30% in pre after reporting better than expected financial results
CYRX – Up over 25% after beating revenue estimates
BTAI – Up over 8% in pre after announcing publication in Frontiers in Pharmacology on the effects of Dexmedetomidine (the active ingredient in BXCL-501) on stress-mediated behaviors in non-clinical studies
*together with Stock Market Media
⏰Let The Countdown Begin⏰
The ONLY Strategy Targetting +1,000% Or Better
Countdown To The Debut Is ON!
HOTLIST🔥
MYGN – Up over 30% in pre after reporting better than expected financial results
Myriad Genetics Inc. (MYGN) is a leader in molecular diagnostic testing and precision medicine.
In the after-hours yesterday, the company announced financial results for its second quarter ended June 30, 2025 and updated its financial guidance on business performance for the full-year 2025.
Highlights include:
Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds of $9.5 million, revenue increased 5% year-over-year.
Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year.
Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-over-year, benefiting from product mix, improving average revenue per test trends, and greater laboratory efficiencies.
Second quarter 2025 GAAP net loss of $330.5 million, or $(3.57) per share, reflecting non-cash impairment charges of $316.7 million due primarily to a decline in Myriad’s market capitalization year-to-date. Adjusted EPS was $0.05 in the second quarter 2025.
On July 31, 2025, entered into a new $200 million credit facility to enhance financial flexibility and support Myriad’s growth strategy.
Raised 2025 revenue guidance to a range of $818 – $828 million, from $807 – $823 million, and reiterated adjusted EPS range of $(0.02) – $0.02,2 reflecting second quarter 2025 results, the interest expense under the new credit facility, and the current business outlook.
Shares of MYGN traded up over 30% in the pre-market in reaction to the better than expected financial results.
The $4.80 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $5, $5.20, $5.40 and then the pre-market high at $5.66. Beyond that $5.83 and a gap fill at $7.27 come into play.
Below $4.80, targets to the downside are $4.66, $4.60, $4.20, $4 and then a gap fill at $3.87.
CYRX – Up over 25% after beating revenue estimates
Cryoport, Inc. (CYRX) is a leading global provider of temperature-controlled supply chain solutions for the life sciences.
In the pre-market this morning, the company announced financial results for its second quarter (Q2) and first half (H1) of 2025.
Highlights include:
Second quarter revenue increased 14% year-over-year to $45.5 million
Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million
Life Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue
Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestiture
Company reaffirms full year 2025 revenue guidance of $165 to $172 million
Shares of CYRX traded up over 25% in the pre-market in reaction to the news.
The $8.10 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $8.50, $8.80 and then the pre-market high at $9.45. Beyond that, $9.75 and $11.20 come into play.
Below $8.10, targets to the downside are $8, $7.50, $7 and then a gap fill at $6.74.
*sponsored by Roku
TV Ads That Perform Like Digital
We have entered a new era of TV advertising where the barriers to entry are lower than ever, and Roku Ads Manager is leading the way.
Growth marketers can access Roku’s audience reach in the US with a self-service ad platform that’s built for performance.
Roku powers 47% of all TV streaming time in the US*, so your brand can run ads alongside premium content and meet your audience where they’re already engaged. *Comscore, 2024
BTAI – Up over 8% in pre after announcing publication in Frontiers in Pharmacology on the effects of Dexmedetomidine (the active ingredient in BXCL-501) on stress-mediated behaviors in non-clinical studies
BioXcel Therapeutics, Inc. (BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience.
The study demonstrated a significant effect in translatable behavioral models related to psychiatric disorders suggesting potential applications of BXCL501 in chronic conditions in addition to treatment of acute agitation.
BXCL501 has already been clinically validated and FDA approved (as IGALMI™) for treatment of acute episodes of agitation associated with bipolar disorder or schizophrenia.
Studies underway at leading academic institutions are investigating the potential of daily dosing of BXCL501 in treating a number of stress-related disorders, including opioid withdrawal, acute stress disorder, and alcohol use disorder in patients with PTSD.
Shares of BTAI traded up over 8% in the pre-market in reaction to the news.
The $3.20 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $3.40, $3.60, $3.77 and then the pre-market high at $3.93. Beyond that, $4, $5 and $5.20 come into play.
Below $3.20, targets to the downside are $3.05 a gap fill at $2.97, $2.90 and then $2.80.
MARKET NEWS 📰
Don’t miss out on our MOBILE ALERTS! Some of these alerts have rocketed past the MOON 🌝. Simply text “RAGE” to 1-(888) 487-1534📲.
*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.
SPONSORED CONTENT & COMPENSATION: You should assume we receive compensation for any non-SV purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies (“Clients”). We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.
CLIENT CONTENT:SV is not responsible for any content hosted on Client sites; it is the Client’s responsibility to ensure compliance with applicable laws.
NOT INVESTMENT ADVICE:Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content, regardless of characterization as “educational,” should be considered promotional and subject to disclosed conflicts of interest. Do NOT rely on this as personalized investment advice. SV strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS NOT TYPICAL: Past performance, testimonials, and historical results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Past newsletters, marketing materials, track records, case studies, and promotional content should NOT be relied upon as indication of future performance. Market conditions, regulatory environments, and individual circumstances vary significantly over time. Actual results will vary widely given factors such as experience, skill, risk mitigation practices, market dynamics and capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
REGULATORY STATUS:Neither SV nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
HIGH-RISK SECURITIES:Securities discussed may be penny stocks, small-cap stocks, cryptocurrencies, options, or other highly speculative investments subject to extreme price volatility, rapid and substantial price movements, limited liquidity, regulatory changes, and potential total loss of value. Market conditions can change rapidly and unpredictably.
LEGAL: In any legal action arising from or related to SV services or these terms, SV shall be entitled to recover attorneys’ fees, costs, and disbursements in addition to any other relief.
